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Background and Objectives: Interferon-gamma is an important cytokine, which 
facilitates immunity against intracellular pathogens. Several factors, including 
genetic variations of cytokine-producing genes have been shown to influence the 
progression and severity of Hepatitis C virus (HCV) infection. 
Methods: Between January and December 2012, 87 HCV-infected individuals 
and 89 individuals without HCV infection were recruited for the study of Single 
Nucleotide Polymorphism (SNP) at Interferon Gamma (IFNG) +874 T/A. After 
extraction of genomic DNA from Peripheral Blood Mononuclear Cells (PBMCs) in 
blood sample of the individuals, Amplification Refractory Mutation System 
(ARMS) polymerase chain reaction was performed to evaluate the SNP at this 
position. 
Results: The frequency of genotype TA was 62.1% in the HCV-infected group, 
while it was 47.2% for the control group (p=0.033). However, after adjusting for 
confounders (including alcohol consumption, drug addiction, transfusion, and 
tattoos), the genotypes at this position did not show any statistically significant 
association with HCV infection (adjusted P values were above 0.05). The frequency 
of allele A was slightly higher in patients than the controls (55.2% versus 
48.3%).Carriers of A allele were more frequent in patients with HCV infection 
compared to the control group (55.17% in patients versus 48.31% in the control 
group; P=0.02). However, after adjustment for confounders, the results were no 
longer statistically significant (P=0.2). 
Conclusion: A carrier status for certain alleles and genotypes at Interferon 
Gamma (IFNG) +874 T/A may lead to higher susceptibility to HCV infection in a 
certain population.  
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Introduction 
Chronic infection with Hepatitis C Virus (HCV) 
may lead to complications such as fibrosis, 
cirrhosis, and Hepatocellular Carcinoma (HCC). 
Half a million new cases of liver cancer have been 
estimated, annually, 22% of which are caused by 
infection with HCV (1). Worldwide, about 130 to 
170 million individuals are infected with Hepatitis 
C Virus (HCV) (2). 
Attempts to develop therapeutic vaccines 
against HCV infection have not so far been very 
successful as a result of variants of HCV, which are 
capable of undergoing extensive mutations that 
confer them new resistance adaptations (3). An 
area that has received extensive attention during 
the recent decades is the study of host immunity 
and its interactions with infectious agents, rather 
than the previously more conventional approach of 
studying variations in infectious agents. It has been 
shown that chronic HCV effects the number, subset 
composition, and functional performance of  
immune cells, including natural killer cells, natural 
killer T cells, dendritic cells, macrophages, and T 
cell (4). Furthermore, genetic variations in host 
genes, which have a role in mediating immunity, 
may affect the regulation and production of 
components required for the two arms of the 
immune system, namely innate and adaptive 
immunity. One of the important components is 
cytokines, which have immune regulatory roles 
and are secreted by the immune cells.  Cytokines 
are capable of suppressing viral replication and 
mediating host immune responses (5). Cytokines 
may show different expression levels, while 
interactions with other components may affect the 
ability of the immune system to combat the 
infection and to reduce or eliminate the virus or its 
associated complications. An estimated 10 million 
Single Nucleotide Polymorphisms (SNPs) are 
assumed to be present in the human genome (6).It 
has been suggested that the rate of expression of 
some cytokines is influenced by mutations in their 
regulatory and coding regions. This, in turn, is 
considered to influence the natural history of HCV 




One of the important cytokines involved in 
suppressing viral infections is Interferon Gamma 
(IFNG), which has clinical implications in 
preventing the development of chronic hepatitis, 
liver cirrhosis, and hepatocellular carcinoma (9). 
The IFNG gene is present on chromosome12q24.1. 
Interferon Gamma-induced signaling pathways 
involved in the activation of genes with antiviral 
properties are very complicated (10). The signaling 
pathway is partly controlled by the Ras-MAPK and 
Jak-STAT pathways (11, 12). Antiviral properties 
of IFNG are mediated through the induction of 
gene expression for double-stranded RNA 
activated Protein Kinase (PKR), 2’-5’ 
oligoadenylate synthetase, and dsRNA-specific 
adenosine deaminase (13). In addition to its role as 
an antiviral agent, IFNG is capable of engaging T 
cells to the site of inflammation (14, 15). The IFNG 
produced by T and Natural Killer (NK) cells can 
mediate the function of T helper cell type 1 (Th1) 
(16) 
The SNP at Interferon Gamma (IFNG) +874 
T/A of the human Interferon-Gammais present at 
the 5' end of the first intron. Polymorphisms 
normally appear in regulatory regions and their role 
in certain diseases has been previously 
investigated. Among these polymorphisms, intron 
1 +874 T/A and C/A repeat microsatellites and 
promoter SNP -179 T/G have been considered 
previously (17). Although some in vitro studies 
showed that IFNG can suppress the replication of 
HCV (18, 19), no correlation has been found 
regarding the expression level of IFN Gand HCV 
viral load (20, 21). 
The current study was performed to evaluate the 
frequency of alleles and genotypes at position +874 
of the IFNG gene between patients infected with 
HCV and individuals without HCV infection in the 
city of Mashhad, northeast of Iran, to determine if 
there is any association between a specific allele or 
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Materials and Methods  
Population study and sample collection 
After receiving the approval from the ethical 
committee of Mashhad University of Medical 
Sciences, 87 HCV-infected patients and 89 healthy 
individuals were recruited from January to 
December 2012 for the study of single nucleotide 
polymorphism at IFNG +874T/A. Informed 
consents were obtained from the studied patient 
and controls. Blood samples were obtained at the 
Microbiology and Virology Research Center of 
Qaem hospital and outpatient clinic of Qaem 
hospital in Mashhad, Iran. Ten- and three-milliliter 
blood samples were obtained from patient and 
control groups, respectively. Blood samples were 
collected in tubes containing EDTA. Genomic 
DNA (for Amplification Refractory Mutation 
System (ARMS) Polymerase Chain Reaction 
(PCR)) was extracted from whole blood using a 
genomic DNA extraction Kit (GeNet Bio, Daejeon, 
Korea). Viral RNA was isolated from sera using 
QIAamp Viral RNA Mini Kit (Qiagen, USA). The 
control group was defined as individuals without 
HCV infection as determined by commercial 
Enzyme Linked Immunosorbent Assay (ELISA) 
kits (Delaware Biotech, USA). Control subjects 
were screened for HBV and HCV markers by 
HBsAg and anti-HCV antibody ELISA kits 
(Delaware Biotech, USA). Hepatitis C Virus-
infected patients were evaluated based on positive 
anti-HCV IgG test results as determined by a 
commercial ELISA kit (Delaware Biotech, USA), 
and HCV RNA, using Reverse Transcriptase (RT)-
PCR, as described previously (22). Hepatitis C 
Virus genotyping was performed using the method 
described by Ohno et al. (23). The HCV RNA load 
was evaluated using Gene Proof HCV real-time 
PCR Kit (Gene Proof a.s., Czech Republic) in 
accordance with the manufacturer’s instructions. 
Three standard concentrations from 102 to 104 
copy/mL were made, and the real-time PCR was 
performed on Rotor Gene (Corbett Research, 
Australia). All known factors involved in the risk 
of HCV transmission, including yet not limited to 
a history of drug and alcohol addiction, transfusion, 
HIV infection, tattoos, working environments such 
as working in hospitals and family history of HCV 
infection, were recorded for the studied sample. A 
summary of demographic and risk factors are given 
in Table 1. 
Table 1. Information on demographic and risk factors in the studied population of HCV patients and control groups 
Characteristics Patients Controls P-Value 
Male: Female 78:9 39:50 <0.05 
Age ( years; mean ± SD ) 42.58+10.28 36.33+12.72 <0.05 
Addiction 37 (42.5%) - <0.05 
Alcohol 34 (39.1%) 2 (2.2%) <0.05 
Transfusion 31 (35.6%) 7 (7.8%) <0.05 
Tattoo 27 (31.0%) - <0.05 
ALT (U/L, mean ± SD) 36.42+30.59 27+21.45 0.06 
Increased ALT* 26 (29.9%) 19 (21.35%) <0.05 
*ALT, alanine aminotransferase with the unit U/L (unit per liter). * >41 U/L for men and >31 U/L for women. 
DNA extraction and genotyping 
Following extraction of DNA, ARMS PCR was 
performed. The primer sequences used for the 
amplification of IFNG+874T/A (238 bp in length) 
were as follows: T allele-specific primer, 5'-
TTCTTACAACACAAAATCAAATCT-3'; A allele-specific 
primer, 5'–TTCTTACAACACAAAATCAAATCA3' and 
reverse primer 5'-TCAACAAAGCTGATACTCCA3'. For 
PCR, the final reaction volume was 20 µL 
including: 1X PCR buffer, 10 pmol forward and 
reverse primers, 10mM MgCl2, 1.5 mMdNTPs, 
and 0.5 unit Taq DNA polymerase (GeNetBio, 
Korea). The PCR program included initial 
denaturation at 96°C for 5 minutes and one cycle 
of 96°C for 130 seconds, 63°C for 60 seconds, and 
72°C for 30 seconds; 9 cycles of 96°C for 10 
seconds, 63°C for 60 seconds, and 72°C for 30 
seconds, followed by 20 cycles of 96°C for 10 
seconds, 60°C for 50 seconds and 72°C for 30 
seconds. The PCR was followed by a final 
extension at 72°C for 5 minutes. Amplified PCR 
products were analyzed by 2.5% agarose gel 
stained with Green Viewer (Pars Tous, Iran).  
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Biochemical analysis 
Alanine aminotransferase levels were 
determined for the studied sample using Pars 
Azmoon Kit (Pars Azmoon, Iran) in accordance 
with the manufacturers’ recommendations. A 
summary of the results of ALT is presented in 
Table 1. Alanine aminotransferase levels 
(determined at 37°C) of < 31 U/L for females and 
< 41 U/L for males were reported as normal. 
Statistical analysis 
Chi-square and Fisher’s exact test were used for 
qualitative comparison. Qualitative comparison 
was performed with t test. Logistic regression was 
used to compare the two groups. Data analysis was 
carried out using IBM SPSS software (IBM Corp., 
Armonk, NY) version 21 (24). P values below 0.05 




The mean age of the patients was 42.58± 10.28 
years while that of the control group was 36.33± 
12.72 years. The age ranged from 16 to 66 years 
and 15 to 65 years in the patient and control groups, 
respectively. Also, among the patient group, 78 
(89.7%) were male and 9 (10.3%) were female. 
While in the control group 39 (43.8%) were male 
and 50 (56.2%) were female (Table 1). The 
duration of treatment with interferon and ribavirin 
varied from one month to two years in patients with 
chronic HCV infection. The authors were not able 
to recruit more females in the patient group firstly 
because the above-mentioned high-risk behaviors 
were more commonly observed among males in the 
studied population and secondly because a lower 
number of females were willing to take part in the 
present study. Real-time PCR was used to evaluate 
HCV load for all participants in the patient group. 
The viral load results for nine patients are shown in 
Figure 1.  
Genetics study 
The agarose gel results of ARMS-PCR for 
several polymorphism statuses at IFNG +874 T/A 
is shown in Figure 2.  
 
 
Figure 1.  Viral Load Results of Nine Patient 
Samples and Three Standards 
Viral load analysis was performed by the Real-time 




Figure 2.  Agarose Gel Result of the Polymerase Chain 
Reaction Products of IFNG Gene +874 T/A 
Polymorphism 
Genotype TA: sample 1 (lanes 1A and 1T), sample 2 
(lanes 2A and 2T), and sample 3 (lanes 3A and 3T); 
genotype AA: sample 4 (lanes 4A and 4T); genotype 
TT: sample 1(lanes 5A and 5T), lane M: 100 bp DNA 
size marker 
 
The current study suggested that the IFNG 
+874T/A gene polymorphism had different 
genotype and allele frequencies between patient 
and control groups. All genotypes in cases and 
controls were in Hardy-Weinberg Equilibrium. 
The frequency of the TA genotype was 62.1% in 
the patients, while it was 47.2% for the control 
group (p=0.033). The frequency of genotype AA 
was almost the same in both groups (24.7% and 
24.1% among control and patient groups, 
respectively). However, after adjusting for 
confounders (including alcohol consumption, drug 
addiction, transfusion, and tattoos), the genotypes 
at this position did not show any statistically 
significant association with HCV infection 
(adjusted P values were above 0.05). The 
frequency of the A allele was slightly higher in 
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patients than the controls (55.2% versus 48.3%), 
while the frequency of the T allele was higher in 
controls than patients (51.7% versus 44.8%) (Table 
2).  
Based on a dominant model, carriers of the A 
allele were more frequent in patients with HCV 
infection compared to the control group (55.17% in 
patients versus 48.31% in the controls; P=0.02). 
However, after adjustment for confounders, the 
results did not remain statistically significant 
(P=0.2) (Table 3). 
 
 
Table 2. Distribution of genotypes and allele frequencies of Interferon-gamma (+874) T/A single nucleotide 








(n = 87 ) 
Frequency 
(%) 
P value OR 95% C.I. 
Genotype Frequencies 
TT 25 28.08 12 13.79 
0.02 0.41 
(0.19-
0.87) AA/AT 64 71.90 75 86.21 
Allele Frequencies 
A 86 48.31 98 55.17 
0.02 1.31 (0.86 1.98) 
T 92 51.69 80 44.83 
 
 
 Table 3. Adjusted* values for genotypes and allele frequencies of Interferon-gamma (+874) T/A single nucleotide 





(n = 89) 
Frequency (%) Patients 
(n = 87 ) 
Frequency (%) P value OR 95% C.I. 
Genotype Frequencies 
AA  22 24.72 21 24.14 Ref 
AT 42 47.19 54 62.07 0.42 0.74 0.36-1.53 
TT 25 28.09 12 13.79 0.14 1.99 0.80-4.95 
AA 22 24.71 21 24.13 
0.93 0.97 (0.49-1.93) 
TT/AT 67 75.27 66 75.85 
TT 25 28.08 12 13.79 
0.4 0.60 (0.20-1.83) 
AA/AT 64 71.90 75 86.19 
Allele Frequencies 
A 86 48.31 98 55.17 
0.20 1.31 (0.86-1.98) 
T 92 51.68 80 44.82 
*Adjusted for alcohol consumption, drug addiction, transfusion and tattoos 
There was no significant association between 
HCV genotypes and IFNG genotypes in patients 
(P>0.05). The study did not find any significant 
association between HCV RNA titer and either the 
HCV genotypes or IFNG genotypes (P>0.05).  
Biochemical assay 
Biochemical results showed that mean ± 
Standard Deviation (SD) of ALT levels in patients 
and controls were 36.42+30.59 and 27.00+21.45, 
respectively (P=0.06). The relationship between 
ALT levels (evaluated based on stratification in 
normal and abnormal ALT level groups) in the 
control and patient groups and common risk factors 
of HCV infection are shown in Figure 3. 
 
Figure 3. The Relationship between Alanine 
Aminotransferase Levels in the Controls and Patients 
and Common Risk Factors of Hepatitis C Virus 
Infection. ALT: alanine aminotransferase 
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Discussion  
The prevalence of HCV was shown to be below 
1% in the general population of Mashhad, 
northeast of Iran, with genotypes 1a (41.7%) and 
3a (33.0%) being the most prevalent genotypes in 
this region (24, 25). As expected, addiction, 
alcohol consumption, transfusion, and tattoos had 
a statistically significant association (p<0.05) with 
HCV infection in the studied population. Although 
higher ALT levels were observed in the patient 
group (ALT (U/L), mean ± SD=36.42+30), 
compared to the control group (ALT (U/L, mean ± 
SD=27+21.45), a statistically significant 
difference was not observed for the ALT levels (p-
value = 0.06). The result of genotype analysis of a 
dominant analysis model of the IFNG +874 T/A 
position (TT vs. AA+AT) indicated that the mixed 
AA+AT genotype was more common in patients 
(p=0.02; OR=0.41, 95% CI: 0.19 - 0.87). 
Viral genetic factors and variations, including 
different genotypes and quasi species of HCV, and 
host factors including, gender, age, duration of 
infection, and history of alcohol intake or diabetes 
could influence the outcome of HCV infection (26, 
27). Ethnicity has been shown to influence the 
inheritance of specific patterns of polymorphisms 
in cytokine genes (28). Polymorphisms in genes 
related to both adaptive and innate immunity are 
considered to be crucial in clearance of HCV 
infection (29).  
Replication of HCV genome and the severity of 
the disease are known to be influenced by the 
expression of the IFNG gene (30). Phenotypically, 
individuals having T/T, T/A, and A/A genotypes at 
this position are high, intermediate, and low 
producers, respectively (31).  
In our study, both genotype and allele 
frequencies at IFNG +874 T/A showed a 
statistically significant association with HCV 
infection (p<0.05). However, after adjustment for 
confounders (alcohol consumption, drug addiction, 
transfusion, and tattoos) the results did not remain 
statistically significant for both allele and genotype 
frequencies (p>005). This may indicate that the 
observed trend in the association of some alleles 
and genotypes with HCV infection was not entirely 
dependent on the polymorphism at this position 
and that the confounders, which are normally 
associated with HCV infection had more profound 
effects.  
The association of IFNG +874 T/A with several 
other infectious diseases has been studied so far. In 
a study from Brazil on patients with ocular 
toxoplasmosis and the control group (without the 
infection), similar to our study, after adjustment for 
confounders, no statistically significant difference 
was observed for A and T alleles (p-value=0.113 
;). In that study, however, unlike our study, which 
indicated an almost similar genotype frequency for 
AA genotype for both groups of HCV-infected 
patients and the control group (about 24% 
genotype frequency of AA in both groups), the AA 
genotype was more frequent in the patient group 
with ocular toxoplasmosis when compared with the 
control group (44% of patients vs. 23% of controls 
had AA) (32). With regards to other infectious 
diseases, a study in Turkey suggested that the TT 
genotype had a higher frequency in patients with 
brucellosis (33). In other studies, the A allele of 
IFNG +874 had also been shown to influence the 
outcome of diseases such as parvovirus and 
tuberculosis (34, 35).  
Several studies have also noted the importance 
of polymorphism at IFNG +874 T/A with Hepatitis 
B Virus (HBV) infection. Among them, a study 
among Korean patients with HBV infection did not 
provide evidence in favor of the association 
between polymorphism at IFNG +874 T/A and 
persistent HBV infection (36). This finding was 
also confirmed in a study on a Turkish population, 
in which no association was found between IFNG 
+874 T/A polymorphism and HBV persistence 
(37). A study sample of patients from North China, 
however, showed the association of AA genotypes 
with persistent infection with HBV, HCV, and 
HBV/HCV co-infection (38). 
With regards to HCV infection, several studies 
provided evidence for the significance of this 
polymorphism on response to treatment and 
severity of the disease. A study from Taiwan on 
chronic HCV infected patients did not suggest any 
association between the inheritance of A or T allele 
at IFNG +874 and response to combination therapy 
with high-dose Interferon (IFN)-alpha and 
ribavirin (39). A similar result was also observed 
among Iranian patients with HCV infection, who 
were treated with Pegylated (PEG)-IFN plus 
ribavirin. In that study, no statistically significant 
difference was observed between allele and 
genotype frequencies between the responder and 
non-responder patients (40). The inheritance of the 
T allele at this position was considered to be 
associated with high rate of cirrhosis compared to 
carriers of homozygote A allele (p-value: 0.028) 
(41). Polymorphism of IFNG was shown to have a 
role in recurrent hepatitis C after transplantation. It 
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was shown in a study that 80% of non-recurrent 
patients had the polymorphism associated with 
higher levels of IFNG production (the T/T 
genotype) (42). 
A study among Tunisian patients with HCV 
infection and a control group, similar to our study, 
indicated no statistically significant difference in 
allele or genotype frequencies between the patient 
and control groups at IFNG +874(43). 
Other SNPs have been reported in IFNG gene 
polymorphisms that may have more profound 
significance, for instance, the -756 G SNP in the 
proximal IFNG promoter region was found to have 
more functional importance in HCV persistence 
(44), and two SNPs in IFNG R2 were found to be 
associated with HBV viremia. Similarly, SNPs 
within IFN-AR2 were reported to have associations 
with persistent HBV infection in Gambia (45). 
 
Conclusion  
Taking into account the result of several studies, 
it seems that ethnicity is partly involved in 
susceptibility to diseases including hepatitis C 
virus, in which genetic polymorphisms may confer 
different levels of risk in different populations. 
Immunity is complex and many pathways, 
including signaling pathways are affected by the 
interaction of environmental and genetic factors. 
The difference in polymorphism of one cytokine 
does not directly influence the severity and the 
progression of a disease; it is rather the collective 
profile of cytokine genes, components of signaling 
pathways and other related genes, which determine 
the outcome. Even in a certain population, more 
accurate observations require a huge sample size 
representing patients with full history of therapies 
they have undergone, risk factors, and relevant data 
over a period of time. For future studies, it is 
preferable to use high-throughput methods of 
genotyping to take into account the combination of 
a larger number of polymorphisms in immune-
related genes and also to recruit a larger sample 
size of patients with a complete set of data. 
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